(Q35623297)

9 August 2017

1 reference

title

Methodological issues and new developments in the economic evaluation of vaccines (English)

1 reference

9 August 2017

3

Pierre Van Damme

1 reference

9 August 2017

Philippe Beutels

1

1 reference

PubMed ID

14711326

9 August 2017

Eddy Van Doorslaer

series ordinal

2

1 reference

PubMed ID

14711326

9 August 2017

Jane Hall

series ordinal

4

1 reference

9 August 2017

1 October 2003

1 reference

Expert Review of Vaccines

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

5

1 reference

9 August 2017

649-660

1 reference

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis

9 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Economic evaluations of varicella vaccination programmes: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Disease extinction and community size: modeling the persistence of measles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Utilitarianism and the measurement and aggregation of quality--adjusted life years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

The hidden costs of infant vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

The cost-effectiveness of varicella vaccine programs for Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Addressing the challenges to immunization practice with an economic algorithm for vaccine selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.5.649

21 January 2018

Identifiers

DOI

10.1586/14760584.2.5.649

1 reference

9 August 2017

1 reference

PubMed ID

14711326